<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Item #</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Column #</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1113</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">SEER</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2016</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">16</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">871 - 871</td>
    </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.metsAtDxBrain<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div>
<div class='content chap10-para'>This field identifies whether brain is an involved metastatic site. The six Mets at Dx-Metastatic Sites fields provide information on specific metastatic sites for data analysis.</div>
<div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div>
<div class='content chap10-para'>Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient&#8217;s metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors.</div>
<div class='content chap10-para'><strong>Codes</strong></div>
<div class='content chap10-para'>
    <table>
        <tr class='code-row'>
            <td class='code-nbr'>0</td>
            <td class='code-desc'>None; no brain metastses</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>1</td>
            <td class='code-desc'>Yes; distant brain metastases</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>8</td>
            <td class='code-desc'>Not applicable</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>9</td>
            <td class='code-desc'>Unknown whether brain is involved metastatic site. Not documented in patient record.
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'></td>
            <td class='code-desc'></td>
        </tr>
    </table>
</div>